Activation of glycolysis rate and glucose uptake by Ang II in ciBAs. (A) ECAR was measured in the control (light grey circles) and ciBAs continuously treated with Ang II at concentrations of either 0.01 μM or 0.1 μM (black diamonds). Glucose, oligomycin, and 2-DG were sequentially added during the measurement, as indicated. (B) ECAR corresponding to glycolysis and glycolytic capacity was calculated in the Ang II-treated ciBAs. (C, D) Either Ang II or the combination of Ang II and telmisartan was added to the control ciBAs during the measurement, as indicated. (E) ECAR corresponding to glycolysis and glycolytic capacity was calculated in ciBAs transiently treated with either Ang II or the combination of Ang II and telmisartan. Data represent mean ± SD (n = 6–8). (F) Glucose uptake was evaluated by the fluorescent probe in ciBAs transiently (30 min) and continuously treated with 0.1 μM Ang II. The area of the staining was quantified using ImageJ software. (G) The phosphorylation of AKT was quantified by immunoblotting in ciBAs treated with either Ang II or the combination of Ang II and telmisartan for 30 min. The band intensities were measured by densitometry using ImageJ software. Data represent mean ± SD (n = 3). p-values were determined using one-way ANOVA with Tukey’s multiple comparison test: *p < 0.05, **p < 0.01, ***p < 0.001, N.S.; not significant.